Market Highlights:
Fosfomycin is a phosphoenolpyruvate analog and a synthetic broad-spectrum antibiotic with antimicrobial and bactericidal properties. Fosfomycin binds to the enzyme enol pyruvate transferase and inactivates it. This leads to an irreversible blocking of the condensation of uridine diphosphate-N-acetylglucosamine with p-enol pyruvate, which is one of the first steps in bacterial cell wall synthesis and ultimately leads to cell lysis and bacterial cell death. Fosfomycin is an orally available broad-spectrum antibiotic that is mainly used to treat uncomplicated urinary tract infections. Fosfomycin is associated with jaundice with a low rate of transient serum enzymes during therapy and with rare cases of clinically apparent acute liver damage. The market study is being classified by Type (Tablets and Injection), by Application (Common Urinary Tract Infection, Postoperative Urinary Tract Infection and Preoperative Prevention of Urinary Tract Infection) and major geographies with country level break-up that includes South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Key Players:
The prominent players in the Fosfomycin Sodium are Merck Group (Germany), AdvaCare Pharma (United States), LGM Pharma (United States), Cipla (India), Northeast Pharmaceutical Group Co. Ltd. (China), Ercros (Spain), SGPharma Pvt. Ltd. (India), Shin Poong Pharm Co. Ltd. (South Korea), Sundent Pharm Group (China) and Hubei Xunda Pharmaceutical (China).

The Distribution Channel, such as Online, is boosting the Fosfomycin Sodium market. Additionally, the rising demand from SMEs and various industry verticals, macro-economic growth are the prime factors driving the growth of the market.

The End-User, such as Hospital Pharmacy, is boosting the Fosfomycin Sodium market. Additionally, the rising demand from SMEs and various industry verticals, macro-economic growth are the prime factors driving the growth of the market.

Major Market Development Highlights
In October 2023, Hikma Pharmaceuticals launched Fosmicin IV (fosfomycin trometamol for injection) in the US market, expanding access to this important antibiotic for treating multidrug-resistant (MDR) Gram-negative bacterial infections.
In December 2023, Spero Therapeutics received FDA approval for Orbactiv (omadacycline), a new tetracycline antibiotic indicated for complicated urinary tract infections (cUTI) and acute bacterial skin and skin structure infections (ABSSSI). Omadacycline has a similar mechanism of action to Fosfomycin Sodium,

Key Questions Answered in the Report
What will the Fosfomycin Sodium Market size and the growth rate be in Future?
What are the key factors driving the Fosfomycin Sodium Market?
What are the key market trends and macro-economic impacting the growth of the Fosfomycin Sodium Market?
What are the challenges to market growth?
Who are the key vendors in the Fosfomycin Sodium Market?
What are the market opportunities and threats faced by the vendors in the Fosfomycin Sodium Market?
Trending factors influencing the market shares of the Players.
What are the key outcomes of the five forces analysis of the Fosfomycin Sodium Market?

Refer complete Table of Content of Fosfomycin Sodium Market Study

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Fosfomycin Sodium market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Fosfomycin Sodium market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Manufacturers of Fosfomycin Sodium, Suppliers and Distributors of Fosfomycin Sodium, End-Users, Potential Investors, Market Research Firms, Regulatory Bodies and Others.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.